Company intelligence / Profile preview

Н

Kirov, Kirov Oblast, Russia

Ownership: Private
Development stage: Other

Overview

Nanolek is a leading Russian vaccine and biotech manufacturer with a strong record in GMP production, supplying pediatric vaccines for large-scale immunization, developing oncology treatments, and offering contract manufacturing for international partners. Over 15 million Russian children have been immunized with Nanolek vaccines; annual turnover for 2024 was 25.3 billion rubles (~$280M)

Therapeutic areas: OncologyInfectious DiseasesRare DiseasesDermatology
Modalities: Small moleculeMonoclonal antibodyEnzyme replacement therapyRecombinant proteinVaccine
Industry: Biotech

Partnerships

“Rather large partners among them” for contract vaccine manufacturing (some foreign partners; specific names not given in the public domain)

Beyond the preview

Go deeper on Н.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Н.

Explore the full profile